Cytokinetics (CYTK) Invested Capital (2010 - 2026)

Cytokinetics (CYTK) has reported Invested Capital for 13 consecutive years, with $44.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Invested Capital rose 245.74% year-over-year to $44.8 million; the TTM figure through Mar 2026 stood at $117.7 million (up 147.62% YoY), while the FY2025 annual figure was $41.2 million, up 257.47% from the prior year.
• Invested Capital climbed to $44.8 million in Q1 2026 per CYTK's latest filing, from $41.2 million in the prior quarter.
• Across five years, Invested Capital topped out at $44.8 million in Q1 2026 and bottomed at $958000.0 in Q4 2022.
• Historically, Invested Capital has averaged $17.1 million across 5 years, with a median of $11.5 million in 2024.
• Annual changes were most pronounced in 2023 — Invested Capital surged 952.19% — and 2025, when it gained 12.5%.
• Cytokinetics' Invested Capital stood at $958000.0 in 2022, then soared by 952.19% to $10.1 million in 2023, then increased by 14.29% to $11.5 million in 2024, then jumped by 257.47% to $41.2 million in 2025, then rose by 8.81% to $44.8 million in 2026.
• Business Quant data shows CYTK's Invested Capital at $44.8 million in Q1 2026, $41.2 million in Q4 2025, and $17.3 million in Q3 2025.